Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results

Stock Track

07/10

Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.

The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.

Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1128639414"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1128639414\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1128639414?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128639414","market":"us","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results","media":"Stock Track","content":"<p>Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.</p><p>The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.</p><p>Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-10 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.</p><p>The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.</p><p>Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1128639414","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128639414","pubTimestamp":1783653296,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.The biotech company announced that its Ryoncil product delivered net...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"股票跟踪 | 由于 Ryoncil 强劲的收入业绩，Mesoblast 盘中飙升 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.The biotech company announced that its Ryoncil product delivered net revenue of US$36 million for the fourth quarter ended June 30, 2026, and US$115 million for the full fiscal year. CEO Dr. Silviu Itescu stated that revenues have already exceeded initial projections and expressed optimism for continued growth in the coming year, citing strong uptake across major U.S. pediatric centers.Ryoncil is the first mesenchymal stromal cell product approved by the FDA for pediatric patients with steroid-refractory acute graft-versus-host disease. The positive financial update appears to have boosted investor confidence in the company's commercial trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}